Sonoma Pharmaceuticals (SNOA)

Overall impact
B (72)

Commentary

Sonoma Pharmaceuticals is a strong overall performer. With a 'B' rating of 72.4 for overall impact (86th percentile compared to all companies), Sonoma Pharmaceuticals ranks 42nd out of 154 industry peers, behind Adamis Pharmaceuticals, Benitec Biopharma, Aquinox Pharmaceuticals and 38 others, and ahead of Assertio Therapeutics, Evolus, DiaMedica Therapeutics and 109 others. On top material causes for Sonoma Pharmaceuticals's industry (Pharmaceuticals & Biotech), Sonoma Pharmaceuticals performs well in Sustainable Use of Natural Resources (87.1 score), Child and Maternal Health (89.6), Child and Maternal Health (92.7) and 7 other causes where it received an 'A' score and performs poorly in Technology Innovation (6.5 score) and Humane Treatment of Animals (29.0).
Impact
Cause SNOA
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
10
Sector
Health Care
Industry
Pharmaceuticals
Sub-industry
Pharmaceuticals
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Co, United States
Share classes
SNOA
Description
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye and nasal care, oral care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. The company offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fissures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl-based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis; and Pediacyn, an atopic dermatitis hydrogel. It also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for use in emergencies and on mucous membranes, cuts, abrasions, burns, and body surfaces; and Endocyn root canal irrigation solutions. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.
Material causes
Ethos considers the following causes material for Sonoma Pharmaceuticals, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.